These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1449966)

  • 1. Positron emission tomography for tumour assessment.
    Jones T; Tilsley DW; Wilson CB; Lammertsma AA; Brown G; Brady F; Price PM
    NMR Biomed; 1992; 5(5):265-9. PubMed ID: 1449966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography imaging of cell proliferation in oncology.
    Kenny LM; Aboagye EO; Price PM
    Clin Oncol (R Coll Radiol); 2004 May; 16(3):176-85. PubMed ID: 15191004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positron emitters for the study of tumor metabolism].
    Strauss LG
    Radiologe; 1989 Jul; 29(7):318-21. PubMed ID: 2667030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.
    Hutchinson OC; Collingridge DR; Barthel H; Price PM; Aboagye EO
    Curr Pharm Des; 2003; 9(11):917-29. PubMed ID: 12678875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic imaging by positron emission tomography in oncology.
    Leskinen S; Lapela M; Lindholm P; Minn H
    Ann Med; 1997 Aug; 29(4):271-4. PubMed ID: 9375982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
    J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET for in vivo pharmacokinetic and pharmacodynamic measurements.
    Gupta N; Price PM; Aboagye EO
    Eur J Cancer; 2002 Nov; 38(16):2094-107. PubMed ID: 12387835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.
    Brady F; Luthra SK; Brown GD; Osman S; Aboagye E; Saleem A; Price PM
    Curr Pharm Des; 2001 Dec; 7(18):1863-92. PubMed ID: 11772355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group.
    Price P; Jones T
    Eur J Cancer; 1995 Nov; 31A(12):1924-7. PubMed ID: 8562143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography.
    Tilsley DW; Harte RJ; Jones T; Brady F; Luthra SK; Brown G; Price PM
    Cancer Surv; 1993; 17():425-42. PubMed ID: 8137352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
    Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; Aboagye EO
    Lancet; 2000 Jun; 355(9221):2125-31. PubMed ID: 10902627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of positron emission tomography to study tumors in vivo.
    Hamberg LM; Hunter GJ; Fischman AJ
    Mol Med Today; 1996 Dec; 2(12):528-34. PubMed ID: 9015794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of positron-emission tomography to study anticancer-drug resistance.
    West CM; Jones T; Price P
    Nat Rev Cancer; 2004 Jun; 4(6):457-69. PubMed ID: 15170448
    [No Abstract]   [Full Text] [Related]  

  • 14. Positron emission tomography. Biomedical research and clinical application.
    Wolf AP; Fowler JS
    Neuroimaging Clin N Am; 1995 Feb; 5(1):87-101. PubMed ID: 7743087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours.
    Ak I; Stokkel MP; Pauwels EK
    J Cancer Res Clin Oncol; 2000 Oct; 126(10):560-74. PubMed ID: 11043393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
    Comans EF; Hoekstra OS; Hoekman K; van der Hoeven JJ; Golding RP; Teule GJ
    Ned Tijdschr Geneeskd; 2000 Aug; 144(32):1520-8. PubMed ID: 10949634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography in oncology.
    Leskinen-Kallio S
    Clin Physiol; 1994 May; 14(3):329-35. PubMed ID: 8026150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography. A new measurement method for imaging of regional and biochemical parameters].
    Bolwig TG; Haunsø S; Hove JD; Hesse B; Højgaard L; Jensen M; Paulson OB; Svendsen JH; Sørensen SS
    Ugeskr Laeger; 1994 Oct; 156(43):6341-7. PubMed ID: 7810006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
    Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of positron emission tomography in oncology.
    Glaspy JA; Hawkins R; Hoh CK; Phelps ME
    Oncology (Williston Park); 1993 Jul; 7(7):41-6, 49-50; discussion 50-2, 55. PubMed ID: 8347460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.